Literature DB >> 23153440

Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease.

Tomohiro Oishi1, Naruhiko Ishiwada, Kousaku Matsubara, Junichiro Nishi, Bin Chang, Kazuyo Tamura, Yukihiro Akeda, Toshiaki Ihara, Moon H Nahm, Kazunori Oishi.   

Abstract

Serotype-specific protective immunity in pediatric patients with invasive pneumococcal disease (IPD) has not been fully investigated. To determine the protective immunity to the infecting serotype, the serotype-specific immunoglobulin G (IgG) levels and opsonization indices (OIs) were examined in 24 Japanese pediatric patients whose serum was collected within one month of an IPD episode between May 2008 and June 2011. The median age (range) of IPD patients was 17 (10-108) months and 63% were boys. In all 17 patients tested, the levels of serotype-specific IgG to the infecting serotype were higher than 0.2 μg/ml, but the OIs to the infecting serotype were <8. The avidities of 19F- or 6B-specific IgG in patients with levels higher than 5.0 μg/ml, but with undetectable OIs, were confirmed to be lower than those in patients with high OIs. Our data demonstrated that although the levels of serotype-specific IgG to the infecting serotype were higher than 0.2 μg/ml in sera of pediatric patients with IPD, the OIs were low one month after the IPD episode. Low opsonic activities in these patients may, in part, be explained by the low avidity of serotype-specific IgG.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153440      PMCID: PMC3829722          DOI: 10.1016/j.vaccine.2012.11.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.

Authors:  Isabelle Henckaerts; David Goldblatt; Lindsey Ashton; Jan Poolman
Journal:  Clin Vaccine Immunol       Date:  2006-03

3.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.

Authors:  Robert L Burton; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-09

6.  Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia.

Authors:  D M Musher; H M Phan; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

7.  Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.

Authors:  L Schuerman; J Wysocki; J C Tejedor; M Knuf; K-H Kim; J Poolman
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

8.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Natural and vaccine-related immunity to Streptococcus pneumoniae.

Authors:  D M Musher; A J Chapman; A Goree; S Jonsson; D Briles; R E Baughn
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

10.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.

Authors:  Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

View more
  14 in total

Review 1.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

2.  Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

Authors:  S Blumental; J C Moïsi; L Roalfe; M Zancolli; M Johnson; P Burbidge; R Borrow; S Yaro; J E Mueller; B D Gessner; D Goldblatt
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

3.  Capsule Switching and Antimicrobial Resistance Acquired during Repeated Streptococcus pneumoniae Pneumonia Episodes.

Authors:  Bin Chang; Akiyoshi Nariai; Tsuyoshi Sekizuka; Yukihiro Akeda; Makoto Kuroda; Kazunori Oishi; Makoto Ohnishi
Journal:  J Clin Microbiol       Date:  2015-08-12       Impact factor: 5.948

4.  Determination of avidity of IgG against protein antigens from Streptococcus pneumoniae: assay development and preliminary application in clinical settings.

Authors:  D C Andrade; I C Borges; N Ekström; T Jartti; T Puhakka; A Barral; H Kayhty; O Ruuskanen; C M Nascimento-Carvalho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-12       Impact factor: 3.267

Review 5.  Streptococcus pneumoniae Serotype Distribution and Pneumococcal Conjugate Vaccine Serotype Coverage among Pediatric Patients in East and Southeast Asia, 2000-2014: a Pooled Data Analysis.

Authors:  Stanley S Tai
Journal:  Vaccines (Basel)       Date:  2016-02-22

6.  Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution.

Authors:  Munehisa Fukusumi; Bin Chang; Yoshinari Tanabe; Kengo Oshima; Takaya Maruyama; Hiroshi Watanabe; Koji Kuronuma; Kei Kasahara; Hiroaki Takeda; Junichiro Nishi; Jiro Fujita; Tetsuya Kubota; Tomimasa Sunagawa; Tamano Matsui; Kazunori Oishi
Journal:  BMC Infect Dis       Date:  2017-01-03       Impact factor: 3.090

7.  Serotypes With Low Invasive Potential Are Associated With an Impaired Antibody Response in Invasive Pneumococcal Disease.

Authors:  Nils Littorin; Fabian Uddén; Jonas Ahl; Fredrik Resman; Hans-Christian Slotved; Simon Athlin; Kristian Riesbeck
Journal:  Front Microbiol       Date:  2018-11-15       Impact factor: 5.640

Review 8.  Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.

Authors:  Angelika Wagner; Birgit Weinberger
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

9.  Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.

Authors:  Kenichi Takeshita; Noriko Takeuchi; Yoshiko Takahashi; Chie Fukasawa; Haruka Hishiki; Tadashi Hoshino; Naruhiko Ishiwada; Naoki Shimojo
Journal:  Hum Vaccin Immunother       Date:  2021-07-02       Impact factor: 4.526

10.  Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.

Authors:  Jenny A Herbert; Emily J Kay; Sian E Faustini; Alex Richter; Sherif Abouelhadid; Jon Cuccui; Brendan Wren; Timothy J Mitchell
Journal:  Vaccine       Date:  2018-05-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.